Education
About Us
Working with TipRanks
Follow Us
Avalo Therapeutics (AVTX)
NASDAQ:AVTX
AVTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.99 - $18.79
Previous CloseN/A
Volume10.82K
Average Volume (3M)89.36K
Market Cap
$70.33M
Enterprise Value-$53.84M
Total Cash (Recent Filing)$3.42M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.34
Next Earnings
May 08, 2025EPS Estimate
-1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-161.42
Shares Outstanding10,671,934
10 Day Avg. Volume63,094
30 Day Avg. Volume89,364
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)97.09
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.01
Enterprise Value/Ebitda1.41
Forecast
1Y Price Target
$33.33Price Target Upside405.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Avalo Therapeutics News
PremiumCompany Announcements
Avalo Therapeutics Appoints Michael Heffernan as Chairman
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityAvalo Therapeutics has a strong financial position with enough capital to sustain operations into 2027.
Management StrengthAvalo Therapeutics is led by a veteran management team with notable transaction experience.
Market OpportunityThe market for hidradenitis suppurativa treatments is expanding, with biologics projected to generate significant revenue, which presents opportunities for Avalo Therapeutics.
Bears Say
Financial PerformanceThe company reported a net loss of $35.3M as it reported a loss of $26.5M in change in fair value of warrant liability.
Potential BiasThe firm providing this analysis may have a conflict of interest, which could affect the objectivity of the report.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AVTX FAQ
What was Avalo Therapeutics’s price range in the past 12 months?
Avalo Therapeutics lowest stock price was $5.99 and its highest was $18.79 in the past 12 months.
What is Avalo Therapeutics’s market cap?
Avalo Therapeutics’s market cap is $70.33M.
When is Avalo Therapeutics’s upcoming earnings report date?
Avalo Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 33 days.
How were Avalo Therapeutics’s earnings last quarter?
Avalo Therapeutics released its earnings results on Mar 20, 2025. The company reported -$2.3 earnings per share for the quarter, missing the consensus estimate of -$0.168 by -$2.132.
Is Avalo Therapeutics overvalued?
According to Wall Street analysts Avalo Therapeutics’s price is currently Undervalued.
Does Avalo Therapeutics pay dividends?
Avalo Therapeutics does not currently pay dividends.
What is Avalo Therapeutics’s EPS estimate?
Avalo Therapeutics’s EPS estimate is -1.18.
How many shares outstanding does Avalo Therapeutics have?
Avalo Therapeutics has 10,671,934 shares outstanding.
What happened to Avalo Therapeutics’s price movement after its last earnings report?
Avalo Therapeutics reported an EPS of -$2.3 in its last earnings report, missing expectations of -$0.168. Following the earnings report the stock price went up 2.879%.
Which hedge fund is a major shareholder of Avalo Therapeutics?
Currently, no hedge funds are holding shares in AVTX
---
Avalo Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.33 (405.77% Upside)
$33.33 (405.77% Upside)
Blogger Sentiment
Bullish
AVTX Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $12.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.59%
12-Months-Change
Fundamentals
Return on Equity
-50.06%
Trailing 12-Months
Asset Growth
618.01%
Trailing 12-Months
Company Description
Avalo Therapeutics
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
---
AVTX Stock 12 Month Forecast
Average Price Target
$33.33
▲(405.77% Upside)
Technical Analysis
Synlogic
―
Corvus Pharmaceuticals
―
X4 Pharmaceuticals
―
Meiragtx Holdings
―
Kezar Life Sciences
―
Best Analysts Covering AVTX
1 Year
1 Year Success Rate
3/19 ratings generated profit
1 Year Average Return
-41.94%
reiterated a buy rating 12 days ago
Copying Leland Gershell's trades and holding each position for 1 Year would result in 15.79% of your transactions generating a profit, with an average return of -41.94% per trade.
---